Vancomycin-resistant enterococci: Mechanisms and clinical observations

Clinical Infectious Diseases

Volumn 33, Issue 2, 2001, Pages 210-219

  Gold, H S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; NITROFURANTOIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; DRUG MECHANISM; ENTEROCOCCUS; INFECTION CONTROL; MEDICAL DECISION MAKING; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DECISION MAKING; ENTEROCOCCUS; GENOTYPE; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LABORATORIES, HOSPITAL; PHENOTYPE; VANCOMYCIN RESISTANCE;

EID: 0035879512     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321815     Document Type: Article

References (77)

1. High-level vancomycin-resistant enterococci causing hospital infections
2. Antimicrobial resistance in intensive care units
3. Antimicrobial-drug resistance
4. Antibiotic resistance in enterococci
5. Characterization of the chromosomal aac(6′)-Ii gene specific for Enterococcus faecium
6. In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole: A pitfall
7. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens
8. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance
9. Nucleotide sequence of the β-lactamase gene from Enterococcus faecalis HH22 and its similarity to staphylococcal β-lactamase genes
10. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States
11. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis
12. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe
13. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin
14. The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147
15. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR(B) two-component regulatory system in Enterococcus faecalis V583
16. Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB-transferable determinant in Streptococcus bovis
17. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
18. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium
19. VanD-type glycopeptide-resistant Enterococcus faecium BM4339
20. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405
21. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants
22. Contribution of VanY d,d-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors
23. Resistance to glycopeptides in enterococci
24. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: Biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA
25. Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis
26. Characterization of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339
27. A cluster of VanD vancomycin-resistant Enterococcus faecium: Molecular characterization and clinical epidemiology
28. Urinary tract infection with an Enterococcus faecalis isolate that requires vancomycin for growth
29. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms
30. Enterococcal-type glycopeptide resistance genes in non-enterococcal organisms
31. Analysis of genes encoding D-alanine:D-alanine ligase-related enzymes in Leuconostoc mesenteroides and Lactobacillus spp [erratum, Gene 1995; 161:139]
32. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147
33. Characterization of Tn1547, a composite transposon flanked by the IS16 and IS256-like elements, that confers vancomycin resistance in Enterococcus faecalis BM4281
34. Genetic linkage and co-transfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate
35. Geographic distribution of a large mobile element that transfers ampicillin and vancomycin resistance between Enterococcus faecium strains
36. Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens
37. vanC cluster of vancomycin-resistant Enterococcus gallinarum BM4174
38. Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals
39. Heterogeneity of the vanA gene cluster in clinical isolates of enterococci from the north-eastern United States
40. Long PCRs of transposons in the structural analysis of genes encoding acquired glycopeptide resistance in enterococci
41. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
42. Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures
43. Characterization of glycopeptide-resistant enterococci from U.S. hospitals
44. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: A meta-analysis
45. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients
46. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
47. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia
48. Detection of vancomycin resistance in Enterococcus species
49. Antimicrobial susceptibility testing: Special needs for fastidious organisms and difficult-to-detect resistance mechanisms
50. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR
51. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus
52. Antimicrobial susceptibility of enterococci: In vitro studies of the action of antibiotics alone and in combination
53. High-level penicillin resistance and penicillin-gentamicin synergy in Enterococcus faecium
54. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections
55. Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin-β-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366
56. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci
57. Vancomycin-resistant enterococci
58. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin
59. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections
60. Quinupristin/dalfopristin: Therapeutic potential for vancomycin-resistant enterococcal infections
61. In vitro activities in new oxazolidinone antimicrobial agents against enterococci
62. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
63. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant, resistant, gram-positive infections
64. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
65. Fosfomycin tromethamine: A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections
66. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium [letter]
67. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium
68. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin
69. Treatment outcomes of vancomycin-resistant E. faecium (VREfm) and vancomycin-resistant E. faecalis (VREfc) compared with vancomycin (V)-susceptible enterococcal bacteremia (EB)
70. Pathogenicity of the enterococcus in surgical infections
71. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces
72. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
73. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers
74. Control of vancomycin-resistant enterococci at a community hospital: Efficacy of patient and staff cohorting
75. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium
76. Clinical and epidemiological significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype)